Metastatic melanoma treatment: Combining old and new therapies

被引：63

作者：

Davey, Ryan J. ^{[1
,2
]}

van der Westhuizen, Andre ^{[3
]}

Bowden, Nikola A. ^{[1
,2
]}

机构：

[1] Univ Newcastle, Fac Hlth, Hunter Med Res Inst, Callaghan, NSW 2308, Australia

[2] Univ Newcastle, Fac Hlth, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia

[3] Calvary Mater Hosp, Dept Med Oncol, Newcastle, NSW, Australia

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2016年 / 98卷

基金：

英国医学研究理事会;

关键词：

Melanoma; Treatment; Targeted therapy; Immunotherapy; Combination therapy; TUMOR-INFILTRATING LYMPHOCYTES; ADOPTIVE CELL TRANSFER; BRAF-MUTANT MELANOMA; LONG-TERM SURVIVAL; PHASE-II; OPEN-LABEL; T-CELLS; ACQUIRED-RESISTANCE; AUTOLOGOUS TUMOR; INHIBITOR RESISTANCE;

D O I：

10.1016/j.critrevonc.2015.11.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastatic melanoma is an aggressive form of cancer characterised by poor prognosis and a complex etiology. Until 2010, the treatment options for metastatic melanoma were very limited. Largely ineffective dacarbazine, temozolamide or fotemustine were the only agents in use for 35 years. In recent years, the development of molecularly targeted inhibitors in parallel with the development of checkpoint inhibition immunotherapies has rapidly improved the outcomes for metastatic melanoma patients. Despite these new therapies showing initial promise; resistance and poor duration of response have limited their effectiveness as monotherapies. Here we provide an overview of the history of melanoma treatment, as well as the current treatments in development. We also discuss the future of melanoma treatment as we go beyond monotherapies to a combinatorial approach. Combining older therapies with the new molecular and immunotherapies will be the most promising way forward for treatment of metastatic melanoma. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

引用

页码：242 / 253

页数：12

共 177 条

[1] Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy [J].

Abbotts, Rachel ;

Jewell, Rosalyn ;

Nsengimana, Jeremie ;

Maloney, David J. ;

Simeonov, Anton ;

Seedhouse, Claire ;

Elliott, Faye ;

Laye, Jon ;

Walker, Christy ;

Jadhav, Ajit ;

Grabowska, Anna ;

Ball, Graham ;

Patel, Poulam M. ;

Newton-Bishop, Julia ;

Wilson, David M., III ;

Madhusudan, Srinivasan .

ONCOTARGET, 2014, 5 (10) :3273-3286

[2] Genetic alterations of PTEN in human melanoma [J].

Aguissa-Toure, Almass-Houd ;

Li, Gang .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2012, 69 (09) :1475-1491

[3] TRANSFORMING RAS GENES FROM HUMAN-MELANOMA - A MANIFESTATION OF TUMOR HETEROGENEITY [J].

ALBINO, AP ;

LESTRANGE, R ;

OLIFF, AI ;

FURTH, ME ;

OLD, LJ .

NATURE, 1984, 308 (5954) :69-72

[4] Immunotherapy for Melanoma: Current Status and Perspectives [J].

Alexandrescu, Doru T. ;

Ichim, Thomas E. ;

Riordan, Neil H. ;

Marincola, Francesco M. ;

Di Nardo, Anna ;

Kabigting, Filamer D. ;

Dasanu, Constantin A. .

JOURNAL OF IMMUNOTHERAPY, 2010, 33 (06) :570-590

[5] MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study [J].

Ascierto, Paolo A. ;

Schadendorf, Dirk ;

Berking, Carola ;

Agarwala, Sanjiv S. ;

van Herpen, Carla M. L. ;

Queirolo, Paola ;

Blank, Christian U. ;

Hauschild, Axel ;

Beck, J. Thaddeus ;

St-Pierre, Annie ;

Niazi, Faiz ;

Wandel, Simon ;

Peters, Malte ;

Zubel, Angela ;

Dummer, Reinhard .

LANCET ONCOLOGY, 2013, 14 (03) :249-256

[6] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].

Atkins, MB ;

Lotze, MT ;

Dutcher, JP ;

Fisher, RI ;

Weiss, G ;

Margolin, K ;

Abrams, J ;

Sznol, M ;

Parkinson, D ;

Hawkins, M ;

Paradise, C ;

Kunkel, L ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116

[7] Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma:: A phase III study [J].

Avril, MF ;

Aamdal, S ;

Grob, JJ ;

Hauschild, A ;

Mohr, P ;

Bonerandi, JJ ;

Weichenthal, M ;

Neuber, K ;

Bieber, T ;

Gilde, K ;

Porta, VG ;

Fra, J ;

Bonneterre, J ;

Saïag, P ;

Kamanabrou, D ;

Pehamberger, H ;

Sufliarsky, J ;

Larriba, JLG ;

Scherrer, A ;

Menu, Y .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1118-1125

[8] CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2 [J].

Bedognetti, D. ;

Spivey, T. L. ;

Zhao, Y. ;

Uccellini, L. ;

Tomei, S. ;

Dudley, M. E. ;

Ascierto, M. L. ;

De Giorgi, V. ;

Liu, Q. ;

Delogu, L. G. ;

Sommariva, M. ;

Sertoli, M. R. ;

Simon, R. ;

Wang, E. ;

Rosenberg, S. A. ;

Marincola, F. M. .

BRITISH JOURNAL OF CANCER, 2013, 109 (09) :2412-2423

[9] Melanoma genome sequencing reveals frequent PREX2 mutations [J].

Berger, Michael F. ;

Hodis, Eran ;

Heffernan, Timothy P. ;

Deribe, Yonathan Lissanu ;

Lawrence, Michael S. ;

Protopopov, Alexei ;

Ivanova, Elena ;

Watson, Ian R. ;

Nickerson, Elizabeth ;

Ghosh, Papia ;

Zhang, Hailei ;

Zeid, Rhamy ;

Ren, Xiaojia ;

Cibulskis, Kristian ;

Sivachenko, Andrey Y. ;

Wagle, Nikhil ;

Sucker, Antje ;

Sougnez, Carrie ;

Onofrio, Robert ;

Ambrogio, Lauren ;

Auclair, Daniel ;

Fennell, Timothy ;

Carter, Scott L. ;

Drier, Yotam ;

Stojanov, Petar ;

Singer, Meredith A. ;

Voet, Douglas ;

Jing, Rui ;

Saksena, Gordon ;

Barretina, Jordi ;

Ramos, Alex H. ;

Pugh, Trevor J. ;

Stransky, Nicolas ;

Parkin, Melissa ;

Winckler, Wendy ;

Mahan, Scott ;

Ardlie, Kristin ;

Baldwin, Jennifer ;

Wargo, Jennifer ;

Schadendorf, Dirk ;

Meyerson, Matthew ;

Gabriel, Stacey B. ;

Golub, Todd R. ;

Wagner, Stephan N. ;

Lander, Eric S. ;

Getz, Gad ;

Chin, Lynda ;

Garraway, Levi A. .

NATURE, 2012, 485 (7399) :502-506

[10] Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies [J].

Besser, Michal J. ;

Shapira-Frommer, Ronnie ;

Itzhaki, Orit ;

Treves, Avraham J. ;

Zippel, Douglas B. ;

Levy, Daphna ;

Kubi, Adva ;

Shoshani, Noa ;

Zikich, Dragoslav ;

Ohayon, Yaara ;

Ohayon, Daniel ;

Shalmon, Bruria ;

Markel, Gal ;

Yerushalmi, Ronit ;

Apter, Sara ;

Ben-Nun, Alon ;

Ben-Ami, Eytan ;

Shimoni, Avichai ;

Nagler, Arnon ;

Schachter, Jacob .

CLINICAL CANCER RESEARCH, 2013, 19 (17) :4792-4800

← 1 2 3 4 5 6 7 8 9 10 →